CLINICAL TRIALS PROFILE FOR FERRIC DERISOMALTOSE
✉ Email this page to a colleague
All Clinical Trials for ferric derisomaltose
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02642562 ↗ | Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN | Active, not recruiting | NHS Greater Glasgow and Clyde | Phase 4 | 2016-08-01 | This study will address whether the additional use of Intravenous (IV) iron on top of standard care will improve the outlook for patients with heart failure and iron deficiency. One group of participants will receive treatment with iron injections and the other group will not receive any iron injections. |
| NCT02642562 ↗ | Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN | Active, not recruiting | University of Glasgow | Phase 4 | 2016-08-01 | This study will address whether the additional use of Intravenous (IV) iron on top of standard care will improve the outlook for patients with heart failure and iron deficiency. One group of participants will receive treatment with iron injections and the other group will not receive any iron injections. |
| NCT02905539 ↗ | A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer | Completed | Saarland University | Phase 4 | 2016-07-01 | The purpose of this study is to determine to what extend a treatment with the iron compounds Iron Isomaltoside 1000 or Ferric Carboxymaltose is leading to hypophosphatemia and to study the potential clinical impact of hypophosphatemia. |
| NCT02905539 ↗ | A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer | Completed | Universität des Saarlandes | Phase 4 | 2016-07-01 | The purpose of this study is to determine to what extend a treatment with the iron compounds Iron Isomaltoside 1000 or Ferric Carboxymaltose is leading to hypophosphatemia and to study the potential clinical impact of hypophosphatemia. |
| NCT02940860 ↗ | Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease | Completed | Pharmacosmos A/S | Phase 3 | 2016-11-29 | Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA). |
| NCT02940886 ↗ | Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) | Completed | Pharmacosmos A/S | Phase 3 | 2016-11-08 | Evaluate safety and efficacy of iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®) compared with iron sucrose (Venofer®), in subjects diagnosed with IDA. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ferric derisomaltose
Condition Name
Clinical Trial Locations for ferric derisomaltose
Trials by Country
Clinical Trial Progress for ferric derisomaltose
Clinical Trial Phase
Clinical Trial Sponsors for ferric derisomaltose
Sponsor Name
